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System xc
- is a sodium-independent electroneutral transporter, comprising a catalytic subunit xCT (SLC7A11),
which is involved in importing cystine. Certain cancers such as gliomas upregulate the expression of system xc
-,
which confers a survival advantage against the detrimental effects of reactive oxygen species (ROS) by
increasing generation of the antioxidant glutathione. However, ROS have also been shown to function as
targeted, intracellular second messengers in an array of physiological processes such as proliferation. Several
studies have implicated ROS in important cancer features such as migration, invasion, and contribution to a
cancer stem cell (CSC)-like phenotype. The role of system xc
- in regulating these ROS-sensitive processes in
glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor in adults, remains
unknown. Stable SLC7A11 knockdown and overexpressing U251 glioma cells were generated and charac-
terized to understand the role of redox and system xc
- in glioma progression. SLC7A11 knockdown resulted in
higher endogenous ROS levels and enhanced invasive properties. On the contrary, overexpression of
SLC7A11 resulted in decreased endogenous ROS levels as well as decreased migration and invasion.
However, SLC7A11-overexpressing cells displayed actin cytoskeleton changes reminiscent of epithelial-like
cells and exhibited an increased CSC-like phenotype. The enhanced CSC-like phenotype may contribute to
increased chemoresistance and suggests that overexpression of SLC7A11 in the context of GBM may con-
tribute to tumor progression. These findings have important implications for cancer management where
targeting system xC
- in combination with other chemotherapeutics can reduce cancer resistance and recur-
rence and improve GBM patient survival.
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Introduction
Glioblastoma multiforme (GBM) is the most commonmalignant primary adult brain tumor and newly diag-
nosed patients have a life expectancy of less than a year
[1,2]. Despite major advances in understanding solid tumor
biology, neuroimaging, improved surgical techniques, and
chemo/radiation therapies, GBM patients inevitably progress
or relapse an average of only 6.9 months after treatment [3]
with 80% of tumors found within 3 cm of the initial resection
site [4]. The origin and development of GBM are complex
and not fully understood, but involve various genetic alter-
ations that confer growth advantages, including, but not
limited to, rapid cell proliferation and aggressive invasion of
the surrounding normal brain tissues. GBM cells are able to
escape the tumor mass and migrate large distances through
the brain parenchyma, and this infiltrative pattern makes tu-
mor cells difficult to target. Thus, understanding the mech-
anisms that promote migration and invasion of glioma cells
could lead to the development of more effective therapeutic
strategies to increase survival of GBM patients.
System xc
- is a sodium-independent membrane trans-
porter involved in the efflux of glutamate along with the
influx of extracellular cystine that is reduced to cysteine, the
rate-limiting precursor for the major antioxidant glutathione
(GSH) [5]. Expression of system xc
- is upregulated in
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gliomas and has been shown to promote redox balance by
maintaining high levels of GSH, which can scavenge or
neutralize reactive oxygen species (ROS), as well as conju-
gate to xenobiotic agents that are then exported out of the cell
[6,7]. In addition, the exported glutamate has been shown to
be involved in glioma invasion by stimulating cell motility.
The released glutamate activates the Ca2+-permeable a-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptor and induces intracellular Ca2+ oscillations that promote
cell migration [8]. Decreasing glutamate release through
pharmacological inhibition of system xC
- was shown to de-
crease chemotactic invasion and migration of the glioma,
which could be rescued with addition of exogenous gluta-
mate. Thus, it has been hypothesized that system xc
- is
involved in promoting survival of glioma under oxidative
stress through increased GSH production as well as pro-
moting tumor cell infiltration into the normal brain through
released glutamate that acts as an autocrine/paracrine mitogen
(migration-promoting signal) for cell motility and invasion.
ROS, including the superoxide anion (O2
-), hydrogen
peroxide (H2O2), and the hydroxyl radical (OH
-), serve as
secondary messengers of signal transduction pathways that
regulate cell proliferation, survival, and apoptosis [9]. There
is accumulating evidence that ROS can also contribute to
tumor progression by activating pathways for tumor inva-
sion and migration [9–11]. Chiu et al. showed that U87
glioma treated with 12-O-tetradecanoylphorbol-13-acetate
(TPA) increased ROS generation that induced invasion/
migration through activation of mitogen-activated protein
kinase (MAPK), matrix metalloproteinase (MMP)-9, and
cyclooxygenase-2/prostaglandin E2, whereas inhibition of
ROS with exogenous antioxidant treatment blocked the
TPA-induced migration/invasion [9].
These findings based on how ROS levels increase migra-
tion/invasion are conflicting with the published data on how
system xc
- plays a role in tumor proliferation, invasion, and
migration. Most of the previous studies showing the contri-
bution of system xc
- to glioma growth, survival, and migration
were performed with pharmacological inhibitors such as sul-
fasalazine, which have numerous off-target effects, and indi-
rectly link system xc
- to cellular functions. Therefore, it is
difficult to draw conclusions as to the role system xc
- plays in
glioma progression. The contribution of system xc
- to tumor
invasion/migration in the context of system xc
- expression in
glioma cells has not been investigated. We circumvented this
problem by genetically modifying the expression of SLC7A11,
the catalytic subunit of system xc
-, to generate stable over-
expressing and knockdown U251 glioma cell lines.
Recently, studies have suggested that a small population of
stem-like cells, termed cancer stem cells (CSCs), or tumor-
initiating cells, is responsible for GBM invasiveness. These
CSCs, enriched with the stem cell marker CD133, showed
greater migratory and invasive properties compared with
matched CD133-negative cells derived from GBM [12]. The
CSCs have been identified on the ability to self-renew, initiate
tumorigenesis, and are resistant to chemotherapeutic agents
[13]. However, CSCs, similar to normal stem cells, are qui-
escent slow-cycling cells with low endogenous ROS levels,
which account for their self-renewal capacity. The low ROS
levels in CSCs can be attributed to decreased ROS genera-
tion, enhanced ROS-scavenging systems, or a combination of
both. CSCs have also been shown to differentially express
various solute carriers (SLCs) [14], but SLC7A11 expression
in CSCs has not yet been thoroughly investigated.
In this study, we show by RNA sequence analysis that sev-
eral genes involved in cell adhesion, migration, and morpho-
genesis are downregulated in the SLC7A11-overexpressing
U251 glioma. We found that the SLC7A11-overexpressing
cells indeed displayed altered cell morphology and cyto-
skeletal changes. These cells were more cuboidal with large
spherical bodies and more diffuse filamentous actin, and this
correlated with decreased migratory and invasive properties.
Conversely, the SLC7A11 knockdown cells displayed more
pronounced filamentous actin at the plasma membrane and
increased invasion. Overexpression of SLC7A11 in U251
glioma cells also resulted in upregulation of the CSC-like
phenotype. These results suggest that high expression of
system xc
- is correlated with an increased CSC-like phe-
notype that may promote tumor recurrence, but not neces-
sarily tumor metastasis/migration.
Materials and Methods
Cell culture
Human glioma cell lines (U251) were purchased from
American Type Culture Collection and cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2mM GlutaMAX (Gibco),
penicillin (100U/mL), and streptomycin (100mg/mL). All
cell cultures were incubated (6% CO2, 37C) in a humidified
chamber. For chemoresistance studies, cells were treated
24h after plating with 300 mM Temozolimide (TMZ; Sigma-
Aldrich) for 72 h. For sphere formation studies, cells were
cultured in DMEM F-12, 50:50 (MediaTech, Inc.), 1M
HEPES, B-27 supplement (Gibco); 0.420U heparin (American
Pharmaceutical Partners), 2 mM GlutaMAX, penicillin
(100U/mL), and streptomycin (100mg/mL) supplemented
with 20ng/mL epidermal growth factor (EGF; R&D Sys-
tems) and 20 ng/mL basic fibroblast growth factor (bFGF;
R&D Systems) every 3 days. Sphere-like cells were sub-
cultured using Accutase (Innovative Cell Technologies, Inc.)
to break clusters into single-cell suspension.
Production of shSLC7A11 and SLC7A11 U251
glioma cell lines
Lentivirus particles were produced by transfection of
HEK 293T cells with 15 mg of human TRC-pLKO.1-
SLC7A11 shRNA (TRCN0000043126; Sigma-Aldrich),
15 mg of pLK01-nontargeting shRNA (Mission shRNA;
Sigma-Aldrich), or 15 mg of a human SLC7A11-pLX304
plasmid (DNASU Plasmid Repository) using calcium phos-
phate coprecipitation. The culture medium was replaced with
fresh 10% FBS in 1·DMEM after 8 h and supernatant was
collected 48h after transfection. After determination of viral
titers, U251 cells were incubated with a viral vector con-
taining the appropriate overexpressing RNA, shRNA, or
control shRNA, using a multiplicity of infection of 0.5.
Blasticidin (1.0mg/mL; Sigma-Aldrich) or puromycin (10mg/
mL; Sigma-Aldrich) selection was used to obtain stable re-
combinant SLC7A11-overexpressing and shSLC7A11 knock-
down U251 cells, respectively. Parental U251 cells served
as controls for SLC7A11-overexpressing cells, while cells
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transduced with an empty vector served as controls for the
SLC7A11 knockdown cells.
RNA sequence data generation and analysis
Sequencing libraries were prepared with the TruSeq RNA
Sample Preparation Kit V2 (Illumina, San Diego) according
to the manufacturer’s protocol with minor modifications, as
previously described [15]. Briefly, 500 ng of total RNA from
each sample was used for polyadenylated RNA enrichment
with oligo dT magnetic beads, and the poly(A) RNA was
fragmented with divalent cations under elevated temperature.
First-strand cDNA synthesis produced single-stranded DNA
copies from the fragmented RNA by reverse transcription.
After second-strand cDNA synthesis, the double-stranded
DNA underwent end repair, and the 3¢ ends were adenylated.
Finally, universal adapters were ligated to the cDNA frag-
ments, and 10 cycles of PCR were performed to produce the
final sequencing library. Library templates were prepared for
sequencing using the cBot cluster generation system (Illu-
mina) with TruSeq SR Cluster V3 Kit. Sequencing run was
performed in single-read mode of 51 cycles of read1 and 7
cycles of index read using the Illumina HiSeq 2500 platform
with TruSeq SBS V3 Kits. Real-time analysis software was
used to process image analysis and base calling. Sequencing
runs generated *40 million single reads for each sample.
The refSeq annotation for the hg19 version of the human
genome was used to create a transcriptome Bowtie [16] index
(version 0.12.7), to which reads were aligned with the fol-
lowing settings: -v 3-a. Gene expression levels were esti-
mated using eXpress [17] (version 1.4.1), and DESeq [18]
was used for evaluating differential expression.
Immunofluorescence microscopy for F-actin
Cells (200,000 cells/well) were plated (12-well plate),
incubated (24 h, 4C), and then fixed [15min, 4% parafor-
maldehyde in phosphate-buffered saline (PBS)]. Cells were
then permeabilized (0.1% Triton X-100; 15min, room tem-
perature). After washes in PBS, cells were incubated with
Alexa Fluor 488 phalloidin (A12379; Molecular Probes;
1:40) for 1 h. After three 5-min washes, cells were mounted in
Dako fluorescent mounting medium and imaged on an LSM
510 Meta inverted 2-photon confocal microscope.
Boyden chamber cell migration assay
In vitro cell migration assays were performed using 8-mm
pore Millicell cell culture inserts (Millipore; P18P01250). A
total of 2.0· 104 cells/0.5mL medium [5% bovine serum al-
bumin (BSA) in DMEM] were placed in the top chamber of
the insert and 10% FBS was placed in the bottom wells to
serve as a chemoattractant. As a negative control, 5% BSA
was added to the bottom of the Transwell. After 6 h of incu-
bation, cells that had migrated through the pores to the bottom
of the insert were detached using Accutase and counted using a
Guava EasyCyte flow cytometer. Additionally, any cells that
fell to the bottom of the well were also counted.
Cell invasion assay
In vitro cell invasion assays were performed using BD Bio-
Coat Matrigel Invasion Chambers (354480; BD Biosciences).
The top surface of each Transwell chamber was coated with
Matrigel matrix to block noninvasive cells from migrating
through 8-mmmembrane pores. A total of 2.5·104 cells/0.5mL
DMEM were placed in the top chamber and bottom wells were
filled with 10% FBS, which served as a chemoattractant. The
cells were incubated at 37C, 6% CO2, for 24h, after which
invasive cells on the bottom surface of the insert were detached
using Accutase and counted using a Guava EasyCyte flow
cytometer.
Adhesion assay
To demonstrate cell attachment, 96-well plates were
coated with either 5 mg/mL fibronectin (BD Biosciences,
NJ) or 5 mg/mL type I collagen (Advanced BioMatrix, San
Diego, CA) in 100 mL PBS overnight at 4C. The plates
were blocked with 2.5mg/mL BSA for 2 h in DMEM at
37C. Cells were trypsinized and 2 · 104 cells were seeded
in each well for 60min at 37C. The culture surfaces were
washed with Dulbecco’s phosphate-buffered saline and
fixed with 10% trichloroacetic acid at 4C for 1 h. Wells
were then washed with dH2O and allowed to air dry, after
which 100 mL of sulforhodamine B solution 0.4% in 1%
acetic acid was added. After 15min of incubation, plates
were washed in 1% acetic acid, allowed to air dry, and
200mL of 10mM Tris base was added to each well. Absor-
bance was read at 570 nm using a SpectraMax M3.
Tumorsphere formation assay
and limiting dilution assay
Cells were cultured for at least 10 days in sphere-forming
medium. Sphere-like cells were subcultured into single-cell
suspension, and cells of ‡90% viability were used for sphere
formation studies. Cells were serially diluted from 500 to 2
cells per well of 96-well plates, as previously described [19].
Cells were cultured in DMEM F-12, 50:50, supplemented
with HEPES, B-27 supplement, pen-strep antibiotics, and
GlutaMAX. Every 3 days, fresh EGF and bFGF were added
to the media, and cultures were analyzed for spheres.
Limiting dilution assay data were analyzed using the ex-
treme limiting dilution algorithm [20].
Flow cytometry
Flow cytometry was performed on cells stained with
Mushasi-1, SOX2, Nestin, and Nanog antibodies (Santa Cruz).
Secondary antibodies used were coupled to either Alexa Fluor
647 or Alexa Fluor 488 (Invitrogen). Intracellular staining was
performed after fixing single-cell suspensions with 2% para-
formaldehyde, permeabilizing with ice-cold 100% methanol,
blocking with PBS/1%BSA for 1 h at 4C, and incubating (30–
45min, room temperature) with the appropriate antibody (1:50)
in PBS/1% BSA. Stained single-cell suspensions were ana-
lyzed using an LSR Fortessa cytometer (BD Biosciences); data
were analyzed using FlowJo 7.6.1.
Cell viability assay
Cell counting kit-8 (Dojindo Molecular Technologies)
was used to measure cell viability according to the manu-
facturer’s protocol. Absorbance was measured at 450 nm
using a SpectraMax M3.
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Statistical analysis
Experiments were performed in at least triplicate and
repeated at least three independent times. Statistical analysis
was calculated using a two-sided Student’s t-test. Differ-
ences are considered statistically significant when P< 0.05.
Results
Differential gene expression in
SLC7A11-overexpressing and knockdown
glioma cells involved in adhesion and migration
RNA sequence analysis was performed to assess gene
expression changes upon SLC7A11 overexpression and
knockdown in U251 glioma. Differential expression analy-
sis revealed over 4,000 differential genes between SLC7A11
overexpression and respective control cells and over 3,000
differential genes when SLC7A11 is knocked down in U251
cells [15]. Gene Ontology (GO) enrichment analysis iden-
tified the number of GO terms that are underrepresented in
the SLC7A11-overexpressing glioma and in the SLC7A11
knockdown glioma compared with respective controls. Re-
presentative GO terms indicate that several genes involved
in regulation of adhesion, migration, and extracellular ma-
trix are downregulated in the SLC7A11-overexpressing gli-
oma compared with control cells (Fig. 1A). GO enrichment
analysis of the SLC7A11 knockdown glioma compared with
control cells revealed that genes involved in the cell leading
edge were downregulated as well as a number of genes
involved in proliferation such as those functioning in mi-
tosis, chromosome organization, and nuclear division were
downregulated (Fig. 1B).
SLC7A11 modification in U251 glioma alters
migration, invasion, and cell adhesion
To assess whether the modulation of genes involved in
migration and adhesion had any functional consequences,
the SLC7A11-modified U251 cells were examined for their
migratory, invasive, and adhesive properties. Cell migration
requires forward movement of the plasma membrane at the
cell leading edge, and despite a downregulation of genes
involved in this process, the SLC7A11 knockdown cells
showed no difference in migration compared with respective
control cells (Fig. 2A). While there was no difference in
migration, there was a significant increase in invasion in
the knockdown cells (Fig. 2B). On the other hand, the
SLC7A11-overexpressing cells exhibited lower migration
(Fig. 2A) and invasion (Fig. 2B) compared with their re-
spective control cells. This was consistent with the down-
regulation of genes in the SLC7A11-overexpressing cells
involved in cell-substrate adhesion, actin and fibronectin
binding, epithelial cell migration, and regulation of che-
motaxis. To assess the impact of downregulation of genes
involved in adhesion and extracellular matrix, cell attach-
ment was analyzed. Surprisingly, SLC7A11-overexpressing
cells had significantly increased cell attachment after 1 h
compared with respective control cells. On the other hand,
SLC7A11 knockdown cells had significantly decreased (P
value = 5.44 · 10-7) cell attachment compared with control
cells (Fig. 2C). Of note, it was observed that the SLC7A11-
overexpressing cells, at or near 100% confluency, released
from the cell culture plate in large sheets indicating that the
adhesive properties of the cells were dynamic.
SLC7A11 overexpression is correlated with altered
cell morphology and cytoskeletal changes
To further assess their adhesive/migratory properties,
morphology of the cells was examined. While the SLC7A11
knockdown cells retained similar astrocytoid morphology
compared with the control cells with well-developed, long,
branching cytoplasmic extensions, the SLC7A11-overexpressing
cells had a cuboidal-like morphology with large spherical
bodies and central nuclei (Fig. 3A). Since actin is critical to
cell adhesion and migration, fluorescent phalloidin stain-
ing was performed to visualize filamentous actin (F-actin).
Whereas both control cells displayed visible, stretched ac-
tin stress fibers with an elongated polarized shape, both
FIG. 1. Gene expression changes upon SLC7A11 over-
expression and knockdown in U251 cells. (A) Representative
GO terms enriched in genes downregulated upon SLC7A11
overexpression. (B) Representative GO terms enriched in
genes downregulated upon SLC7A11 knockdown. GO en-
richment analysis was carried out using FuncAssociate [42].
GO, gene ontology.
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SLC7A11-modified cells had actin cytoskeleton changes
(Fig. 3B). The SLC7A11 knockdown cells displayed more
pronounced F-actin staining at the plasma membrane, while
some cells displayed an absence of elongated stress fibers and
staining only at the plasma membrane. On the other hand, the
SLC7A11-overexpressing cells displayed more diffuse, cyto-
plasmic F-actin staining (Fig. 3B). The redistribution of F-
actin from the cell membrane to the cytoplasm correlated
with SLC7A11-overexpressing cells exhibiting lower migra-
tion (Fig. 4A) and invasion (Fig. 4B).
SLC7A11-overexpressing U251 cells develop
a more CSC-like phenotype
The growth of the SLC7A11-overexpressing glioma as tight
cuboidal cells in a sheet resembled epithelial-like cells, while
the elongated astrocytoid morphology of SLC7A11 knockdown
cells resembled the more invasive mesenchymal cells. It has
been hypothesized that as cancer cells undergo this epithelial–
mesenchymal transition (EMT), which includes loss of cell–
cell junctions and restructuring of the cytoskeleton, there is
enhanced tumorigenicity and a correlation with increased
CSC-like properties [2]. To test whether the SLC7A11-
modified cells have an altered differentiation state, we cul-
tured the parental SLC7A11 overexpression and SLC7A11
knockdown U251 cell lines in CSC-enriching media. Within
7–10 days, the SLC7A11-overexpressing cells formed large
(*300mm in diameter) tumorspheres, indicative of the pres-
ence of cancer stem/progenitor cells. In contrast, SLC7A11
knockdown, parental, and empty vector cells formed either
much smaller spheres (£50mm) or cell aggregates (Fig. 4A).
Additional analysis by tumorsphere formation assay
showed that SLC7A11-overexpressing cells formed signifi-
cantly more tumorspheres than did the SLC7A11 knock-
down, parental, and empty vector cells as early as 4 days,
and the number of tumorspheres formed by the SLC7A11-
overexpressing cells drastically increased by day 12 (Fig. 4B).
A limiting dilution assay revealed an increased frequency of
cancer stem/progenitor cells in the SLC7A11-overexpressing
cell line (Fig. 4C). A secondary and tertiary tumorsphere
formation assay was performed to obtain a more highly
enriched stem/progenitor cell population versus a more het-
erogeneous population in the primary spheres [21]. The
SLC7A11-overexpressing U251 glioma cells had significantly
FIG. 2. Modification of
SLC7A11 in U251 glioma is
correlated with altered cell
migratory, invasive, and ad-
hesive properties. (A) Boyden
chamber migration assay,
(B) Matrigel invasion assay,
and (C) adhesion assay in
SLC7A11-overexpressing and
knockdown gliomas com-
pared with respective control
cells. Error bars indicate SD;
***P < 0.001, NS= not signi-
ficant. SD, standard deviation.
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higher numbers of tumorspheres formed at secondary and
tertiary passage, which correlate with the number of multi-
potential stem cell/progenitor cells present in the popula-
tion (Fig. 4D). The SLC7A11 knockdown and empty vector
controls formed very few tumorspheres with numbers
comparable with the parental controls (data not shown).
To further confirm that a higher percentage of SLC7A11-
overexpressing cells showed a CSC-like phenotype, we
performed intracellular staining for the CSC-associated
markers, Nanog, Musashi-1, Sox-2, and Nestin. Flow cyto-
metry analysis revealed that all four CSC-associated markers
were more highly expressed in the SLC7A11-overexpressing
cells compared with the SLC7A11 knockdown, parental, and
empty vector cells (Fig. 5).
Characterization of SLC7A11-overexpressing glioma cells
has also revealed that they have increased chemoresistance
to TMZ due to increased GSH levels and increased mito-
chondrial respiration [15]. Recent studies suggest that CSCs
also mediate chemoresistance in various tumors, including
glioma. We hypothesized that overexpression of SLC7A11
in U251 glioma, which promotes a CSC-like phenotype,
also renders the cells resistant to chemotherapy. After en-
riching CSCs in the parental and SLC7A11-overexpressing
U251 lines, we dissociated the tumorspheres into a single-
cell suspension and treated them with 300 mM TMZ. Even
though the viability decreased in both the CSC-enriched
parental and SLC7A11-overexpressing gliomas after TMZ
treatment, the SLC7A11-overexpressing cells still main-
tained higher viability than control cells treated with TMZ
(Fig. 6).
Discussion
Recurrence in GBM patients is inevitable even with
maximal resection due to the highly invasive behavior of the
tumor. Brain tumors have an ability to invade the sur-
rounding healthy brain tissue. These migratory cells can also
travel large distances where they can form recurrent tumors
at both adjacent and distant sites in the brain. Therefore, it
is necessary to understand the molecular mechanisms in-
volved in glioma migration and invasion so that new ap-
proaches can be found to treat the cells left behind after
surgical resection.
GBM utilizes highly metabolic reactions that generate O2
-,
H2O2, HO
, HOCl, and 1O2 as by-products. Whereas HO
 can
rapidly inactivate proteins and degrade lipids and nucleic acids
resulting in cell damage, O2
- and H2O2 are often implicated in
cellular signaling and transcription. The role of ROS in mi-
gration, invasion, and EMT has been well established where
ROS activates the MAPK signaling cascade and nuclear
factor-kappaB pathway leading to activation of target genes
such as urokinase plasminogen activators/MMPs and EMT
genes [22]. We have shown that system xc
- transporter is in-
volved in regulating endogenous ROS levels and modulating
oxidative stress [15]. In this work, we have identified SLC7A11
overexpression in glioma as a potential novel mechanism
contributing to GBM dissemination and tumorigenesis.
For glioma cells to migrate, it requires a change in mor-
phology where the cell becomes polarized, and membrane
protrusions develop, including extensions at the leading
edge, with subsequent cytoskeletal contractions that allow
advancement forward [23]. Our data show that SLC7A11-
overexpressing gliomas have a cuboidal-like morphology
with large spherical bodies that are not conducive to migra-
tion, while the SLC7A11 knockdown cells retain an elongated
polarized shape with more pronounced F-actin staining at the
plasma membrane. It may be plausible that the high endog-
enous ROS levels in the SLC7A11 knockdown cells promote
actin polymerization and cytoskeleton remodeling, leading to
cell migration. Actin polymerization induced by Rac 1, an
upstream regulator of the ROS-producing enzyme NOX, has
been shown to be stimulated by increased O2
- levels, and
antioxidant treatment suppressed the actin elongation [24,25].
Antioxidants such as N-acetylcysteine have also been shown
FIG. 3. SLC7A11 overexpression in U251 glioma is corre-
lated with altered cell morphology. (A) Representative bright-
field images showing the cell morphology of SLC7A11-
modified U251 glioma compared with respective control
cells. Scale bars: 200mm. (B) Representative fluorescent im-
ages of phalloidin staining to selectively label F-actin in
SLC7A11-overexpressing, knockdown, and respective control
cells. Scale bars: 50mm.
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to dampen the activity of coffin, an actin-binding protein that
modulates lamellipoda formation [26].
The SLC7A11-overexpressing glioma cells, which exhibit
low endogenous ROS levels, display significantly reduced
migration and invasion, which is consistent with their
morphology. Since ROS serve as signaling molecules, it
may be that the cells lack sufficient signaling for stimulation
of migration/invasion. ROS can oxidize critical cysteine
residues in signaling molecules involved in cell migration
such as in protein kinase C, an activator of receptor tyrosine
FIG. 4. SLC7A11 overexpression is correlated with increased tumorsphere formation. (A) Photomicrographs of SLC7A11-
modified U251 and control cells after 10 days of culture in CSC-enriching or normal media, scale bars, 300 and 100mm,
respectively. (B) SLC7A11-modified U251 and control cells were cultured for a total of 12 days in CSC-enriching media.
Numbers of tumorspheres formed at indicated time points were calculated. Data shown are means from a representative
experiment. (C) Limiting dilution analysis of frequencies of sphere-forming cells present after 14 days of culture for SLC7A11-
modified U251 and control cells. (D) SLC7A11-modified U251 and control cells were cultured for a total of 12 days in CSC-
enriching media. Number of tumorspheres was counted before single-cell dissociation and replating for another 12 days of
enrichment in CSC-enriching media for secondary tumorsphere cultures and again for tertiary cell cultures. Data shown are
mean–SD from a representative experiment. **P< 0.01; ***P< 0.001. CSC, cancer stem cell.
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kinases (RTKs), as well as in negative regulators of RTKs
such as protein tyrosine phosphatases [22]. Increased ROS
production activated by growth factor receptors has been
shown to increase cell migration in vascular smooth muscle
cells [27] and in endothelial cells [28]. Higher ROS levels in
SLC7A11 knockdown glioma cells likely activate important
signaling pathways involved in the increased cell invasion.
EMT has been recognized as a crucial process in pro-
gression of certain cancers such as breast cancer. During
EMT, cells that are epithelial-like, which are characterized
by an immobile, aligned, and tightly packed phenotype,
undergo a transition to a more mesenchymal-like state
characterized by mobilization and detachment, invasion
and migration, and resistance to anchorage dependence
[29]. After circulating/migrating cells reach secondary
sites with a conducive microenvironment, they undergo a
reverse transition known as mesenchymal-to-epithelial tran-
sition (MET). ROS have been shown to activate signaling
pathways involved in induction of EMT [30]. It is interesting
that the SLC7A11-overexpressing cells with low endogenous
ROS levels exhibit a more epithelial-like phenotype, while the
SLC7A11 knockdown cells with higher endogenous ROS lev-
els exhibit a more mesenchymal-like phenotype. An important
characteristic of EMT is loss of intracellular adhesion where
increased ROS levels have been implicated in intracellular
dissociation [31,32]. The SLC7A11-overexpressing glioma
did exhibit higher adhesion, while the SLC7A11 knockdown
cells showed lower adhesion compared with respective con-
trol cells. It is important to note that EMT and MET are not
FIG. 5. SLC7A11 overexpression is correlated with an increase in CSC-associated markers. Flow cytometric analyses of
expression levels of the CSC-associated markers, Nanog, Musashi-1, Sox-2, and Nestin, in SLC7A11-modified and control
cells after culture in CSC-enriching media.
FIG. 6. CSC-enriched SLC7A11-overexpressing U251 cells
maintain higher viability under basal conditions and when
treated with Temozolomide (TMZ) compared with control
cells. Single cells were plated after 2-week enrichment for
CSCs and then treated with or without 300mM TMZ. Via-
bility was measured after 72 h of treatment. Data shown are
mean–SD from a representative experiment. Data shown are
mean–SD from a representative experiment where *** in-
dicates P< 0.001.
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mutually exclusive and cancer cells exhibit epithelial–mes-
enchymal plasticity. Additionally, ROS induction of EMT is
not absolute, but is cellular context and tissue-type dependent
[33]. While EMT has been studied extensively in breast
cancer, strong evidence of the existence of EMT in GBM is
still lacking [34]. Thus, further investigation is warranted to
examine whether SLC7A11 modification can promote EMT-
like and MET-like changes in GBM.
Cancer-associated EMT contributes to the generation of
cell populations with stem-like characteristics [30]. Since
CSCs have been suggested to be responsible for GBM in-
vasiveness and EMT, and ROS levels seem to play an im-
portant role in CSC self-renewal, we hypothesized that
overexpression of SLC7A11 levels in glioma may promote a
CSC-like phenotype. Therefore, we enriched the CSC-like
population in the SLC7A11-modified and control glioma
cells. Compared with SLC7A11 knockdown and control
cells, the SLC7A11-overexpressing cells showed greater
tumorsphere formation and a higher frequency of sphere-
forming cells, both of which are indicative of an increased
CSC-like phenotype. In addition, SLC7A11 overexpression
correlated with increased expression of the progenitor/
stem cell markers, Musashi-1, Nanog, Sox-2, and Nestin,
which are also CSC-associated markers. It is possible that
SLC7A11 overexpression drives the maintenance of CSCs
because redox balance plays an important role in stem cell
renewal [35,36]. Despite reports that CSCs exhibit EMT
and increased invasive properties, we did not see a corre-
lation between the increased CSC-like phenotype in the
SLC7A11-overexpressing glioma cell and invasiveness/
migration. However, Brabletz et al. proposed that CSCs
can switch back and forth between a stationary/prolifera-
tive phenotype and a migratory/invasive phenotype to
promote growth of the tumor core and colonization of the
neighboring normal tissue [37]. This theory may explain
the observations made with SLC7A11-overexpressing cells.
CSCs have been shown to express various membrane
transporters of the SLC series as well as ATP-binding
cassette (ABC) transporters. For instance, ABCB5 is ex-
pressed on a distinct subset of chemoresistance, stem cell
phenotype-expressing tumor cells in melanoma [38]. Indeed,
ABC transporters are expressed at higher levels in the dis-
tinct side population of tumor cells with stem-like charac-
teristics that may account for the more efficient secretion of
chemotherapeutics from CSCs and thus render them more
resistant [39]. The quiescence of stem cells also protects
them from chemo- and radiotherapy and therefore CSCs
may be responsible for tumor reoccurrence in glioma. Si-
milar to normal stem cells, certain subsets of CSCs in breast
tumors, when compared with nontumorigenic cells, have
lower ROS levels that contributed to their radioresistance
[40]. These CSCs maintained low endogenous ROS levels
due to upregulation of free radical scavenging systems, such
as GSH. Furthermore, expression of one of the CD44+
variant isoforms (CD44v) in CSCs was shown to interact
and stabilize the xCT subunit in gastrointestinal cancer
cells, contributing to the upregulation of GSH synthesis
[41]. Since several studies suggest that CSCs may mediate
chemoresistance, we wondered whether overexpression of
SLC7A11 may render glioma cells resistant to chemotherapy
by promoting the CSC-like phenotype. Indeed, the SLC7A11-
overexpressing cells enriched for the CSC-like phenotype still
retained higher viability after TMZ treatment compared with
control U251 cells enriched for the CSC-like phenotype and
treated with TMZ. Thus, the SLC7A11-overexpressing glioma
cells may have decreased chemosensitivity to TMZ not only
due to increased GSH levels [15] but also due to an increased
CSC-like phenotype.
ROS are known to actively participate in alterations
in cell structure required for migration and cytoskeletal
dynamics, in the expression of adhesion molecules, and
activation of signaling processes involved in cell migra-
tion [26]. The altered cell morphology and changes in
the invasive and migratory phenotype of the SLC7A11-
modified cells most likely are reflective of their low en-
dogenous ROS levels based on cystine/cystine-mediated
GSH generation. While cancer metastasis involves local
invasion and dissemination of cancer cells to distant sites,
the outgrowth of micrometastatic cells into macroscopic
metastases is associated with self-renewal, a well-defined
characteristic of CSCs [2]. Previously, we have shown
that generation of stable SLC7A11-overexpressing glioma
cells demonstrated characteristics of higher GSH gener-
ation and lower ROS production [15]. Surprisingly, we
found that overexpression of SLC7A11 levels in glioma is
correlated with an increased CSC-like phenotype. This
may also be reflective of low endogenous ROS levels since
high ROS levels can lead to stem cell differentiation and loss
of stem-like characteristics.
In conclusion, we have shown that overexpression of
SLC7A11 in glioma is correlated with a less migratory
CSC-like phenotype that may contribute to GBM pro-
gression by tumor cell planting and chemoresistance.
Further studies are warranted to explore whether the ob-
served results are strictly GSH mediated, involve com-
pensatory strategies, or involve alternative pathways. The
contributions of ROS to pathways that regulate cell prolif-
eration, invasion, migration, survival, and apoptosis have
only begun to be elucidated. Clearly, system xc
- plays an
important role in maintaining redox balance by promoting
GSH generation. It will be necessary to decipher the path-
ways that are affected by upregulation of the transporter and
determine whether targeting the transporter in cancer cells
may provide improved clinical outcome in patients diag-
nosed with GBM.
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